Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

08/17/2020, Monday

Media Contacts:
Nathan Molinari
(917) 325-7463



Next Generation Material Infused with Proprietary ProBalance Technology to Help Maintain Ocular Surface Homeostasis and Help Reduce Contact Lens Dryness, Which Affects More Than Half of Lens Wearers in the United States


BRIDGEWATER, N.J., August 17, 2020 -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the launch of Bausch + Lomb INFUSE silicone hydrogel (SiHy) daily disposable contact lens, the only SiHy daily disposable designed with a next generation material infused with ProBalance Technology to help maintain ocular surface homeostasis and help reduce symptoms of contact lens dryness, which is experienced by approximately half1 of the 45 million lens wearers in the United States.2,3

Contact lenses, by nature, alter the balance of ocular surface homeostasis. This can lead to symptoms of dryness and discomfort. Bausch + Lomb INFUSE contact lenses feature a next-generation SiHy daily disposable lens material (kalifilcon A) and ProBalance Technology that work together to help maintain ocular surface homeostasis to help reduce contact lens dryness and discomfort. The ProBalance Technology formula includes the osmoprotectants - erythritol and glycerin, and the electrolyte - potassium, inspired by the TFOS (Tear Film and Ocular Surface Society) DEWS II (Dry Eye Workshop) report.

“We’re proud to announce the availability of our latest innovation, the Bausch + Lomb INFUSE SiHy daily disposable lens, engineered with our most advanced proprietary contact lens technologies,” said John Ferris, vice president and general manager, U.S. Vision Care, Bausch + Lomb. “Bausch + Lomb has combined an advanced material with the latest science to engineer a breakthrough new lens, designed to help maintain ocular surface homeostasis and deliver all-day-comfort, addressing the unmet need of dryness associated with lens wear.”

The ProBalance Technology formula also includes two moisturizers to help retain hydration, provide a smooth, wettable surface and maintain tear proteins in a healthy state. ProBalance Technology is infused into the lens material during the manufacturing process. These proprietary ingredients are released during lens wear. Bausch + Lomb INFUSE combines exceptional breathability for healthy lens wear with the highest moisture content and lowest modulus among SiHy daily disposables*, and it maintains 96% of its moisture for a full 16 hours.

“Many of my patients believe they have to sacrifice moisture for vision correction due to contact lens dryness. I’m excited to be able to offer them a new lens design that goes beyond material characteristics to look at how the lens material and solution technology can work together,” said Arthur B. Epstein, O.D., Director of Clinical Research and the Dry Eye and Ocular Surface Disease Center, Phoenix Eye Care. “By understanding the ocular environment in which a contact lens resides, Bausch + Lomb was able to address patients’ needs by seeking a different approach and design that helps maintain ocular surface homeostasis to help reduce symptoms of contact lens dryness.”

For more information on Bausch + Lomb INFUSE contact lenses visit and

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.




*Versus leading silicone hydrogel daily disposables, DAILIES TOTAL1 and ACUVUE OASYS 1-DAY, based on dollar share of segment.

INFUSE is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.

1. National Institutes of Health.
2. American Optometric Association.
3. Centers for Disease Control and Prevention.


Number of views (8315)/Comments (0)